BrandWikiReturn

BioLineRx

BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.

Corporate history

The firm was established in 2003 as a joint venture of Teva, Hadasit Bio-Holdings, the Jerusalem Development Authority, Yehuda Zisapel, and other investors.[2] It executed an initial public offering on the Tel Aviv Stock Exchange in February 2007, raising 211 million NIS ($50 million) – the TASE's largest biotech IPO until that time.[3][4] In July 2011 BioLine's ADRs began trading on the NASDAQ Capital Market.[5][6] In January 2012, the firm announced a deal with Genoscience, a French pharmaceutical company to jointly develop and market the BL-8020 compound, as a treatment for Hepatitis C.[7] At the end of 2014, Novartis acquired a 12.8% stake in the company as a strategic move to gain access to Israeli-sourced drug candidates.[8]

Management

Morris Laster, (M.D.) an alumnus of. Downstate Medical Center, was CEO of BioLineRx until 2009. He was replaced by Kinneret Savitsky, alumnus of Tel Aviv University early in 2010.[9] Savitsky was replaced as CEO by BioLine COO Philip Serlin on October 10, 2016.

Operations

BioLineRx is a drug development company When promising compounds are discovered, the firm leads them through preclinical trials and engages other companies to further develop them into commercializable drugs.[10] The company entered into its first major commercialization agreement in 2009 when it partnered with Ikaria Holdings Inc. to develop its BL-1040 compound.[11] In 2010, BioLine entered into a commercialization agreement with Cypress Bioscience Inc. for development of its BL-1020 compound. The agreement with Cypress was canceled in 2011 when the company was taken over by Ramius LLC.[12]

Pipeline

Below is a partial list of drug compounds in various stages of development by BioLineRx. Unless indicated otherwise, they have not obtained regulatory approval in relation to the diseases cited.

  • BL-1010 – orally available neuropathic pain[13]
  • BL-1020 – orally available GABA-enhanced antipsychotic for treatment of schizophrenia[14]
  • BL-1021 – orally available small molecule for treatment of neuropathic pain[15]
  • BL-1040 – liquid polymer injected into patients with acute myocardial infarction, invented by Smadar Cohen of Ben-Gurion University[16][17]
  • BL-1230 - a selective cannabinoid receptor type 2 (CB2R) agonist for Dry Eye Syndrome (DES) [18]
  • BL-5010 – cream treatment for seborrheic keratosis skin lesions[19]
  • BL-7040 – orally available anti-inflammatory drug invented by Hermona Soreq of the Hebrew University of Jerusalem[20]
  • BL-8020 – orally administered treatment for Hepatitis C, developed by Philippe Halfon, co-founder and President of Genoscience.
  • BL-8030 – second-generation NS3 protease inhibitor for oral treatment of Hepatitis C, invented by Philippe Halfon[21]

See also

  • TA BlueTech Index
  • List of Israeli companies quoted on the Nasdaq

External links

References

  1. BLRX Profile: BioLineRx Ltd. Stock Yahoo! Finance, 2011, retrieved 28 November 2011^
  2. Yigal Grayeff. BioLineRx signs 3 deals to develop drugs The Jerusalem Post, 13 January 2005, retrieved 28 November 2011^
  3. Omri Cohen. Biotech comes of age: Bioline floats at half-billion shekel market cap TheMarker, 7 February 2007, retrieved 28 November 2011^
  4. Laura Rheinheimer. BioLineRx raises $50m. in TASE's largest biomedical IPO The Jerusalem Post, 8 February 2007, retrieved 28 November 2011^
  5. BioLineRx ADRs Begin Trading on NASDAQ 25 July 2011, retrieved 27 April 2019^
  6. Tova Cohen. BioLineRX ADRs to begin trading on Nasdaq Monday Reuters, 24 July 2011, retrieved 30 June 2017^
  7. Lu Wang. Achillion, BioLineRx, J&J Snack, Rubicon: U.S. Equity Movers 24 January 2012^
  8. Novartis Makes $10M Investment in BioLineRx Genetic Engineering & Biotechnology News, 16 December 2014^
  9. Kinneret Livnat Savitsky Ph.D.: Executive Profile & Biography Bloomberg Business, retrieved 21 February 2015^
  10. David Brinn. BioLineRx—Israel's biotech supermarket ISRAEL21c, 3 June 2007, retrieved 28 November 2011^
  11. Shiri Habib-Valdhorn. BiolineRX earns $10m milestone payment Globes, 28 April 2010, retrieved 28 November 2011^
  12. Gali Weinreb. BiolineRX and Cypress cancel schizophrenia drug agreement Globes, 11 May 2011, retrieved 28 November 2011^
  13. BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic Pain^
  14. Israeli co to hold clinical trial for treatment of Schizophrenia in India The Hindu Business Line, 24 November 2011, retrieved 28 November 2011^
  15. BioLineRx. BioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain 13 September 2011, retrieved 28 November 2011^
  16. Bioline looks to heart attack treatment clinical trial Globes, 27 February 2011, retrieved 28 November 2011^
  17. US company buys exclusive license for Israeli heart attack drug for $285 million Israel21c, 8 July 2009, retrieved 28 November 2011^
  18. Other www.biolinerx.com^
  19. Sharon Wrobel. Bioline RX Gets European Device Confirmation for Bl-5010 Drug Bloomberg, 15 September 2011, retrieved 28 November 2011^
  20. BioLineRx has acquired the rights to compound BL-7040 from Yissum and Prof. Soreq The Hebrew University of Jerusalem, The Edmond and Lily Safra Center for Brain Sciences, 27 June 2011, retrieved 28 November 2011^
  21. BioLineRx signs pact with Genoscience & RFS Pharma to develop and commercialize BL-8030 to treat hepatitis C Pharmabiz.com, 8 February 2012, retrieved 8 February 2012^